The Investment Column: Zeneca attraction's in the price

David Barnes' refusal to suffer fools gladly was in evidence yesterday as he branded press stories about the imminent demise of Zeneca's independence as "fictional and irresponsible".

His irritation has a point. The constant barrage of stories circulating about his company must be placing a serious strain on a workforce that knows full well it is operating in a fast consolidating industry.

But staff anxieties apart, the stories about a takeover of Zeneca are probably wide of the mark for the prosaic reason that nobody could afford to buy the company and take the goodwill write-off it would involve. Shareholders' funds of pounds 1.9bn have a market value of almost pounds 14bn. A bid might run to the best part of pounds 20bn.

Even if anyone could afford to swoop, they would have a job persuading Zeneca's shareholders that they would not be better served sticking with the incumbent management who are doing a tidy job. The spin-off from ICI was, admittedly, fortuitously timed, but it is hard to argue with a 70 per cent outperformance of the market since the middle of 1993.

The promise of earnings growth of an average 15 per cent a year for the next five years is a bold pledge, even if it is no more than the company has achieved over the past two years. But it is a useful pointer to the sustainability of profits growth now Zeneca has created what some analysts see as the best new product portfolio in the industry.

Zeneca received 42 new product approvals in the six months to June, as many as it achieved in all of 1995. The decision to leave the balance sheet almost ungeared, to give the scientists and not the accountants the scope to take risks, appears to have paid off.

Certainly half-way figures showing pre-tax profits up 21 per cent to pounds 610m (pounds 506m) were impressive enough. Sales rose 16 per cent to pounds 2.94bn, with drugs sales ably supported by a strong performance from agrochemicals, earnings per share were 20 per cent better at 42.9p and the dividend increased from 11.25p to 12.5p.

Two factors are driving Zeneca's share price. On fundamental valuation measures it is firmly in the pack of US and European pharmaceuticals majors and rather cheaper on a comparison of future growth rate with price/earnings ratio than, for example, Merck.

Those considerations, however, are likely to continue playing second fiddle to bid speculation which will remain a substantial prop to the share price. While the deal may be too big a mouthful at current levels, were the price to fall significantly rumours would certainly re-emerge and see the price rise again. As a result the shares, down 20p to 1,431p, are likely to fluctuate in a relatively narrow range and there is little scope for outperformance.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Sheridan Maine: Regulatory Reporting Accountant

Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Ashdown Group: Marketing Services Manager - (communications, testing, DM)

£32000 - £35000 per annum + benefits: Ashdown Group: Marketing Services Manage...

Guru Careers: Finance Account Manager

£Neg. (DOE) + Excellent Benefits: Guru Careers: A Finance Account Manager with...

Ashdown Group: Java Developer - Hertfordshire - £47,000 + bonus + benefits

£40000 - £470000 per annum + bonus: Ashdown Group: Java Developer / J2EE Devel...

Day In a Page

Homeless Veterans appeal: 'You look for someone who's an inspiration and try to be like them'

Homeless Veterans appeal

In 2010, Sgt Gary Jamieson stepped on an IED in Afghanistan and lost his legs and an arm. He reveals what, and who, helped him to make a remarkable recovery
Could cannabis oil reverse the effects of cancer?

Could cannabis oil reverse effects of cancer?

As a film following six patients receiving the controversial treatment is released, Kate Hilpern uncovers a very slippery issue
The Interview movie review: You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here

The Interview movie review

You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here
Serial mania has propelled podcasts into the cultural mainstream

How podcasts became mainstream

People have consumed gripping armchair investigation Serial with a relish typically reserved for box-set binges
Jesus Christ has become an unlikely pin-up for hipster marketing companies

Jesus Christ has become an unlikely pin-up

Kevin Lee Light, aka "Jesus", is the newest client of creative agency Mother while rival agency Anomaly has launched Sexy Jesus, depicting the Messiah in a series of Athena-style poses
Rosetta space mission voted most important scientific breakthrough of 2014

A memorable year for science – if not for mice

The most important scientific breakthroughs of 2014
Christmas cocktails to make you merry: From eggnog to Brown Betty and Rum Bumpo

Christmas cocktails to make you merry

Mulled wine is an essential seasonal treat. But now drinkers are rediscovering other traditional festive tipples. Angela Clutton raises a glass to Christmas cocktails
5 best activity trackers

Fitness technology: 5 best activity trackers

Up the ante in your regimen and change the habits of a lifetime with this wearable tech
Paul Scholes column: It's a little-known fact, but I have played one of the seven dwarves

Paul Scholes column

It's a little-known fact, but I have played one of the seven dwarves
Fifa's travelling circus once again steals limelight from real stars

Fifa's travelling circus once again steals limelight from real stars

Club World Cup kicked into the long grass by the continued farce surrounding Blatter, Garcia, Russia and Qatar
Frank Warren column: 2014 – boxing is back and winning new fans

Frank Warren: Boxing is back and winning new fans

2014 proves it's now one of sport's biggest hitters again
Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas